Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Medicine & Life Sciences

• Residual Neoplasm 100%
• Breast Neoplasms 60%
• Drug Therapy 55%
• Survival 52%
• Progression-Free Survival 30%
• Hormones 28%
• Cohort Effect 17%
• National Cancer Institute (U.S.) 7%
• Neoadjuvant Therapy 7%
• National Institutes of Health (U.S.) 6%
• Kaplan-Meier Estimate 6%
• Neoplasms 6%
• Proportional Hazards Models 5%
• Communication 5%
• Research Personnel 4%
• Health Care Outcome Assessment 4%
• Pathology 4%
• Therapeutics 3%